disitamab vedotin
seagen,rongchang pharma
['gyn', 'pancreatic', 'rc48']
rc48-adc combined with radiotherapy, pd-1/pd-l1 inhibitor, gm-csf, and sequential il-2 (prag3.0 regimen) orr was 38.5%, and the dcr was 69.2%. the orr was 66.7% in gynecological cancer, 25.0% in pancreatic cancer, and 31.3% in other cancers. 